Douglas D. Taylor is an entrepreneur and former academic researcher in the field of extracellular vesicles.
Taylor attained a bachelor's degree from the University of Richmond and a Ph.D. from Wake Forest University. He was a post-doctoral fellow at Boston University. [1] Taylor was a professor and Vice Chair for Research in the Department of Obstetrics, Gynecology, and Women's Healthheld at the University of Louisville in Kentucky. [1][ when?] He was also on the faculty of the University of California, Davis. [2][ when?] From 2013 to 2015, he was the Chief Scientific Officer of Aethlon Medical's wholly owned subsidiary, Exosome Sciences. [3] [4]
Taylor first described exosomes in the 1980s, originally believing them to be cell fragments. [5] He later wrote that exosomes could potentially be used as biomarkers for profiling in ovarian cancer biopsies, and could extend their utility to screening other asymptomatic areas. [6] What constitutes exosomes has not been defined; specifically, markers of exosomes do not exist. [7]
In 2015, the Journal of Immunology retracted a paper it published in 2006 and which Taylor had co-written [8] after an "institutional research misconduct investigation committee determined that multiple figures in the...paper were falsified". [9] [10] Taylor responded to the retraction on the blog Retraction Watch, disputing various aspects of the retraction, and stating that he sent "copies of the original data so that the [journal's] editor could independently verify that no falsification or fabrication occurred". [10]
Douglas D. Taylor is an entrepreneur and former academic researcher in the field of extracellular vesicles.
Taylor attained a bachelor's degree from the University of Richmond and a Ph.D. from Wake Forest University. He was a post-doctoral fellow at Boston University. [1] Taylor was a professor and Vice Chair for Research in the Department of Obstetrics, Gynecology, and Women's Healthheld at the University of Louisville in Kentucky. [1][ when?] He was also on the faculty of the University of California, Davis. [2][ when?] From 2013 to 2015, he was the Chief Scientific Officer of Aethlon Medical's wholly owned subsidiary, Exosome Sciences. [3] [4]
Taylor first described exosomes in the 1980s, originally believing them to be cell fragments. [5] He later wrote that exosomes could potentially be used as biomarkers for profiling in ovarian cancer biopsies, and could extend their utility to screening other asymptomatic areas. [6] What constitutes exosomes has not been defined; specifically, markers of exosomes do not exist. [7]
In 2015, the Journal of Immunology retracted a paper it published in 2006 and which Taylor had co-written [8] after an "institutional research misconduct investigation committee determined that multiple figures in the...paper were falsified". [9] [10] Taylor responded to the retraction on the blog Retraction Watch, disputing various aspects of the retraction, and stating that he sent "copies of the original data so that the [journal's] editor could independently verify that no falsification or fabrication occurred". [10]